Yes, fluconazole and phenytoin can be taken together, but the combination is a documented moderate-severity interaction that requires monitoring. Fluconazole can increase the amount of phenytoin circulating in your bloodstream by interfering with how your body breaks down phenytoin. Because phenytoin has a narrow therapeutic window—meaning the difference between an effective dose and a potentially harmful one is relatively small—this increase in blood levels can be clinically significant, and healthcare providers typically recommend monitoring phenytoin serum levels when both drugs are used.
According to the U.S. National Library of Medicine drug labeling data, the interaction between fluconazole and phenytoin is classified as moderate severity. The documented effect is that fluconazole may increase phenytoin serum levels, and monitoring of phenytoin levels is recommended.
The documented mechanism of this interaction is inhibition of CYP2C9—a liver enzyme responsible for metabolizing (breaking down) phenytoin. This source record comes from NLP-processed phenytoin drug labeling and was last updated in May 2026.
This is a source-of-record interaction documented in FDA drug labeling. It is not a theoretical possibility or a rare case report; it reflects established pharmacokinetic understanding that clinicians are expected to account for when prescribing these two drugs together.
Your liver contains many enzymes that break down medications so your body can eliminate them. CYP2C9 is one of those enzymes. Phenytoin is metabolized primarily by CYP2C9 (along with CYP2C19). When fluconazole enters your system, it binds to and inhibits—or slows down—CYP2C9 activity. Think of it as reducing the number of workers on a production line; the output (breakdown of phenytoin) decreases, and phenytoin accumulates in your bloodstream.
Phenytoin is an antiepileptic drug (also called an anticonvulsant) used to prevent seizures. Its therapeutic effect—the dose range where it stops seizures without causing toxicity—is narrow. A typical therapeutic serum level is between 10 and 20 micrograms per milliliter. Levels above this range can cause ataxia (loss of coordination), nystagmus (involuntary eye movements), cognitive impairment, and other central nervous system effects. Levels below the range may not prevent seizures. Because fluconazole can raise phenytoin levels without a change in your prescribed dose, the concentration can drift into the toxic range.
Fluconazole is an antifungal medication commonly used to treat fungal infections such as candidiasis (yeast infections) and other invasive fungal diseases. It is known to inhibit multiple cytochrome P450 enzymes, including CYP2C9, CYP2C19, CYP3A4, and others. This broad inhibitory profile is why fluconazole appears in multiple drug-interaction warnings, not only with phenytoin.
The source record explicitly states that the mechanism is inhibition of CYP2C9. This is not speculation; it is the established pharmacokinetic basis for why fluconazole increases phenytoin levels. General background: CYP2C9 inhibition can occur via competitive binding, non-competitive inhibition, or mechanism-based (irreversible) inhibition, depending on the drug. For fluconazole, literature indicates competitive and possibly non-competitive inhibition of CYP2C9, but the source record does not specify which type. What matters clinically is that the inhibition occurs and that phenytoin levels rise as a result.
This interaction is relevant to anyone taking both fluconazole and phenytoin. There are no special subgroups mentioned in the source record. However, from general pharmacological principles:
The source record does not identify a specific high-risk population; all patients on this combination warrant the recommended monitoring.
Suppose a patient has been taking phenytoin 300 mg daily for seizure control, with serum levels consistently in the therapeutic range (12–18 micrograms per milliliter). The patient then develops a vaginal yeast infection and is prescribed fluconazole. Within days to a week, the inhibition of CYP2C9 begins to slow phenytoin breakdown. The phenytoin level creeps upward—perhaps to 22 or 28 micrograms per milliliter—even though the dose has not changed. Without monitoring, the patient might develop ataxia, dizziness, or cognitive slowing and incorrectly assume these are unrelated symptoms. With phenytoin level monitoring, the increase is caught early, and the prescriber can adjust the phenytoin dose downward to maintain therapeutic levels, or consider an alternative antifungal if appropriate.
The magnitude of CYP2C9 inhibition can be dose- and duration-dependent. A short course of fluconazole (e.g., 3–5 days) might produce a smaller increase in phenytoin levels than a longer course (weeks). The source record does not specify which durations of fluconazole therapy require monitoring, so this detail should be confirmed with a pharmacist. The key point is that the interaction is not instantaneous; it develops over the time fluconazole is present and active in the body, and it resolves gradually after fluconazole is stopped.
If you are taking phenytoin and your healthcare provider prescribes fluconazole, or if you are considering both medications, here are source-grounded questions and considerations to raise:
This article explains a documented interaction based on FDA drug labeling sourced through the National Library of Medicine. It is not a substitute for professional medical or pharmaceutical advice. If you are taking fluconazole and phenytoin or considering both, check your complete medication list at checkdruginteractions.com and confirm all medication decisions with your pharmacist or physician before making any changes.
CDI checks every pair across up to 20 drugs — backed by FDA and NIH data.
Drug interaction data sourced from U.S. FDA drug labeling via openFDA and the U.S. National Library of Medicine (NLM), National Institutes of Health. For informational purposes only. Always consult your pharmacist or physician before making any medication decisions.
A major documented interaction between omeprazole and methotrexate can elevate methotrexate levels. Learn what the evidence shows and wha...
Learn about the documented moderate interaction between empagliflozin and diuretics, how it affects fluid balance, and what monitoring yo...
Amiodarone significantly increases risk of muscle damage from simvastatin. FDA limits simvastatin to 20 mg daily with amiodarone.